Serosurvey in SARS-CoV-2 inactivated vaccine-elicited neutralizing antibodies against authentic SARS-CoV-2 and its viral variants.

Abstract

Various variants of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) have been emerging and circulating in different parts of the world. Millions of vaccine doses have been administered globally, which reduces the morbidity and mortality of coronavirus disease‐2019 efficiently. Here, we assess the immune responses of individuals after two shots of BBIBP‐CorV or CoronaVac inactivated vaccine. We measured neutralizing antibody responses after the second vaccination by using authentic SARS‐CoV‐2 and its viral variants. All the serum samples efficiently neutralized SARS‐CoV‐2 wild‐type lineage, in contrast, a part of serum samples failed to neutralize Alpha, Beta, Gamma, Delta, or Eta lineages, and only several serum samples were able to neutralize Omicron lineage virus strains (BA.1 and BA.2) with low neutralization titer. As compared with the neutralization of SARS‐CoV‐2 wild‐type lineage, the neutralization of all other SARS‐CoV‐2 variant lineages was significantly lower. Considering that all the SARS‐CoV‐2 mutation viruses challenged the antibody neutralization induced by BBIBP‐CorV and CoronaVac, it is necessary to carry out a third booster vaccination to increase the humoral immune response against the SARS‐CoV‐2 mutation viruses.